Please upgrade your browser.
Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line RCC Treatment
The combination of gemcitabine plus capecitabine and sunitinib (GCS) shows activity in metastatic renal cell carcinoma (mRCC).
mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma
Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors.
MicroRNAs (miRNAs) are endogenous small non-coding RNAs that have a pivotal role in the post-transcriptional regulation of gene expression and their misregulation is common in different types of cancer.
Anti-tumor effect of ribavirin in combination with interferon-alpha on renal cell carcinoma cell lines in vitro
Ribavirin is an anti-viral drug; however, recent data suggest that it may also be effective in cancer therapy.
The vascular endothelial growth factor (VEGF) pathway blockers and mammalian target of rapamycin (mTOR) inhibitors have dramatically improved the treatment options and outcome for patients with advanced renal cell carcinoma (RCC).
Focal Therapy and Imaging in Prostate and Kidney Cancer
Professor Dilts has some suggestions how to improve the situation.
Dr. Bavesh Balar is a board-certified hematologist and oncologist on staff at CentraState Medical Center in Freehold, N.J.
You can be a part of an important study being conducted by researchers at Northwestern University.
The application deadline is September 25, 2014. Recipients will be announced in April 2015.
|Powered by NeonCRM|